Milosevic M, Voruganti S, Blend R, Alasti H, Warde P, McLean M, Catton P, Catton C, Gospodarowicz M
Department of Radiation Oncology, Ontario Cancer Institute/Princess Margaret Hospital and University of Toronto, Canada.
Radiother Oncol. 1998 Jun;47(3):277-84. doi: 10.1016/s0167-8140(97)00232-6.
It is necessary to include the entire prostate in the high dose treatment volume when planning radical radiation for patients with prostate cancer. We prospectively compared magnetic resonance imaging (MRI) to computed tomography (CT) and urethrography as means of localizing the prostatic apex.
Thirty patients with clinically localized prostate cancer had a sagittal T2-weighted MRI scan and a conventional axial CT scan performed in the treatment position prior to the start of radiotherapy. Twenty of these patients had a static retrograde urethrogram performed at simulation. The position of the MRI and CT apices were localized independently by two radiation oncologists. In addition, the MRI apex was localized independently by a diagnostic radiologist. The urethrogram apex, defined as the tip of the urethral contrast cone, was easily identified and was therefore localized by only one observer.
There was good interobserver agreement in the position of the MRI apex. Interobserver agreement was significantly better with MRI than with CT. There were no systematic differences in the position of the MRI and CT apices. However, the MRI apex was located significantly above and behind the urethrogram apex. There was poor correlation between MRI and CT and between MRI and urethrogram in the height of the apex above the ischial tuberosities. There was 83% agreement between MRI and CT and 80% agreement between MRI and urethrogram in the identification of patients with a low-lying apex. The apex, as determined by MRI, was <2 cm above the ischial tuberosities and therefore potentially under-treated in 17% of the patients.
MRI is superior to CT and urethrography for localization of the prostatic apex. All patients undergoing radiotherapy for prostate cancer should have localization of the apex using MRI or a technique of equal precision to assure adequate dose delivery to the entire prostate and to minimize the unnecessary irradiation of normal tissues.
在为前列腺癌患者规划根治性放疗时,有必要将整个前列腺纳入高剂量治疗体积内。我们前瞻性地比较了磁共振成像(MRI)、计算机断层扫描(CT)和尿道造影作为定位前列腺尖部的方法。
30例临床局限性前列腺癌患者在放疗开始前于治疗体位进行了矢状位T2加权MRI扫描和常规轴位CT扫描。其中20例患者在模拟定位时进行了静态逆行尿道造影。MRI和CT尖部的位置由两名放射肿瘤学家独立定位。此外,MRI尖部由一名诊断放射科医生独立定位。尿道造影尖部定义为尿道造影剂圆锥的尖端,易于识别,因此仅由一名观察者定位。
MRI尖部位置的观察者间一致性良好。MRI的观察者间一致性明显优于CT。MRI和CT尖部的位置没有系统性差异。然而,MRI尖部明显位于尿道造影尖部的上方和后方。在坐骨结节上方尖部的高度方面,MRI与CT以及MRI与尿道造影之间的相关性较差。在识别低位尖部患者方面,MRI与CT之间的一致性为83%,MRI与尿道造影之间的一致性为80%。由MRI确定的尖部位于坐骨结节上方<2 cm,因此17%的患者可能接受的治疗不足。
MRI在前列腺尖部定位方面优于CT和尿道造影。所有接受前列腺癌放疗的患者都应使用MRI或同等精度的技术进行尖部定位,以确保向整个前列腺提供足够的剂量,并尽量减少对正常组织的不必要照射。